Record-breaking Wearables Brand MyKronoz Gently Ribs Traditional Watchmakers in New Campaign
Intentionally timed to coincide with the world’s biggest show for watches and jewelry, Baselworld 2018, premier watchmaker for the smart generation MyKronoz, has launched a digital campaign that goes beyond category clichés, and pokes fun at old-school watches and their wearers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180327005607/en/
MyKronoz newest video campaign: I'm a watch / I'm a smartwatch (Photo: MyKronoz)
Playfully contrasting the legacy-focused world in which owners of classic timepieces live with that of today’s connected generation, MyKronoz subtly introduces viewers to its groundbreaking hybrid smartwatch ZeTime – an affordable timepiece for traditional watch lovers who also want a smart device.
Debuting on social platforms, six spots in the ‘I’m a watch, I’m a smartwatch’ campaign portray two rival, quirky characters who respectively personify the watch and the smartwatch, and hint at the superiority of a hybrid device like ZeTime, which combines the best of two worlds.
In one spot we see classic watch man sitting meekly with an hourglass on his all but empty desk. By contrast, smartwatch man next to him is busy mixing the decks, taking phone calls, checking the weather and reviewing a map. "What (kind of work) do you do?" he asks, looking over at his unremarkable neighbour.
"Well, I tell the time…." .
"Nice!" replies smartwatch man, charitably.
Sarah Brault, MyKronoz CMO commented, “At a time when the watch market is facing key challenges and most wearable makers are not attending Baselworld 2018, we at MyKronoz are consciously bucking the trend and investing. This campaign is testament to our belief that great design, essential features, affordable prices and a creative approach to our marketing is what will set us apart from the rest.”
In its first five days the spots have been viewed over 2 million times on Facebook and Instagram.
MyKronoz recently broke crowdfunding records, raising over $8,000,000 for ZeTime in a year. This makes ZeTime the most crowd-funded hardware product of 2017, the highest funded hybrid smartwatch ever and MyKronoz the most funded European company in Kickstarter history.
ZeTime belongs to the fast-growing segment of hybrid smartwatches – a subcategory that will make up over 50% of the smartwatches market by 2022. Nearly 80 million hybrid smartwatches will be shipped by 2022, up 460% from an estimated 14 million in 2017 according to IDC. (These figures contrast with shipments of traditional Swiss watches, which decreased by 4.3% in 2017).
About ZeTime: The world's first hybrid smartwatch with mechanical hands over a color touchscreen, ZeTime offers the classic design of a Swiss timepiece with most advanced features of a smartwatch. MyKronoz’s proprietary ‘Smart Movement’ technology enables ZeTime’s always-on hands to function for up to 30 days with a single charge, ensuring the primary function of the watch – to tell time – is always running. With a retail price starting at $199, the hybrid device is available in two different case sizes (39mm and 44mm) and displays (1.05 inch and 1.22-inch). ZeTime boasts three collections comprising a variety of watch case finishing and bands, to appeal to a wide audience.
About MyKronoz: Founded in January 2013, MyKronoz is a Swiss company headquartered in Geneva that designs and develops wearable devices to expand and facilitate the connected experience of the smart generation. Bringing together the essence of watchmaking tradition with innovative technology, MyKronoz offers a full range of affordable and stylish wearables, starting at a price point of $39 only, spanning across 4 product categories: activity trackers, smartwatches, hybrid smartwatches and watch phones, all compatible with iOS and Android.
Present in more than 40 countries, carried by major retailers and partners worldwide (Orange, Auchan, Carrefour, Amazon, Best Buy...), MyKronoz has sold more than 3 million products and established itself as a fierce challenger to both tech and traditional watchmakers.
MyKronoz is part of BOW Group, a global player in the Internet of Things (IoT), operating worldwide in the wearables, connected vehicles and smart home markets. In July 2015, BOW raised €10 million from NextStage AM in series A funding round and closed in November 2017 its $23.5 million series B funding lead by PM Equity Partner, the corporate venture fund of Philip Morris International.
Creative credits: The « I’m a watch; I’m a smartwatch » campaign was co-created with YZ, a creative digital marketing agency based in Paris, Berlin and soon London. YZ is a protean, internationally focused team that mixes creativity, a design-thinking approach to idea generation and brand reputation management expertise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180327005607/en/
Contact information
MyKronoz
Media:
Annabel Corlay
press@mykronoz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom